Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report issued to clients and investors on Friday. The firm set a “sell” rating on the stock.

SYRS has been the subject of several other research reports. HC Wainwright reiterated a “neutral” rating and set a $1.00 price target (down previously from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, Syros Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $3.33.

Syros Pharmaceuticals Price Performance

NASDAQ SYRS opened at $0.21 on Friday. The company has a fifty day moving average price of $0.23 and a 200-day moving average price of $2.04. Syros Pharmaceuticals has a 1 year low of $0.18 and a 1 year high of $7.96. The firm has a market cap of $5.55 million, a price-to-earnings ratio of -0.07 and a beta of 1.31.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same period in the prior year, the business earned ($1.35) earnings per share. On average, research analysts anticipate that Syros Pharmaceuticals will post -2.94 EPS for the current fiscal year.

Insider Buying and Selling at Syros Pharmaceuticals

In other news, Director Nancy A. Simonian sold 134,713 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $0.27, for a total transaction of $36,372.51. Following the transaction, the director now directly owns 41,070 shares of the company’s stock, valued at approximately $11,088.90. This trade represents a 76.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 12.26% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Syros Pharmaceuticals stock. Exome Asset Management LLC raised its holdings in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by 87.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 298,575 shares of the company’s stock after purchasing an additional 139,400 shares during the period. Exome Asset Management LLC owned 1.11% of Syros Pharmaceuticals worth $642,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 91.47% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.